BMJ Learning - Benign prostatic hyperplasia: treatment in primary care

被引：18

作者：

Patel, Anand K. ^{[1
]}

Chapple, Christopher R. ^{[1
]}

机构：

[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

来源：

BRITISH MEDICAL JOURNAL | 2006年 / 333卷 / 7567期

关键词：

URINARY-TRACT SYMPTOMS; TAMSULOSIN; THERAPY; MEN; SAFETY; TOLERABILITY; DUTASTERIDE; FINASTERIDE; MANAGEMENT; DOXAZOSIN;

D O I：

10.1136/bmj.38946.616551.BE1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：535 / 539

页数：5

共 22 条

[1] Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia [J].

Andriole, GL ;

Kirby, R .

EUROPEAN UROLOGY, 2003, 44 (01) :82-88

[2]

[Anonymous], ARI40001 GLAXOSMITHK

[3] Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system [J].

Barendrecht, MM ;

Koopmans, RP ;

De La Rosette, JJMCH ;

Michel, MC .

BJU INTERNATIONAL, 2005, 95 :19-28

[4] Intraoperative floppy iris syndrome associated with tamsulosin [J].

Chang, DF ;

Campbell, JR .

JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2005, 31 (04) :664-673

[5]

CHAPPLE C, 2006, MALE LOWER URINARY T, P143

[6] The oral controlled absorption system (OCAS®):: The evolution of tamsulosin for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) [J].

Chapple, CR .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (07) :20-22

[7] Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician [J].

Chapple, CR .

BJU INTERNATIONAL, 2004, 94 (05) :738-744

[8] Tamsulosin 0.4 mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH) [J].

Chapple, CR ;

Baert, L ;

Thind, P ;

Hofner, K ;

Khoe, GSS ;

Spangberg, A .

EUROPEAN UROLOGY, 1997, 32 (04) :462-470

[9] Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile [J].

Crawford, ED .

BJU INTERNATIONAL, 2005, 95 :1-5

[10] Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials [J].

Edwards J.E. ;

Moore R.A. .

BMC Urology, 2 (1) :1-17

← 1 2 3 →